Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Inflammation, non-endothelial dependent coronary microvascular function and diastolic function-Are they linked?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Acinar cystic transformation of the pancreas: Report of a case and a review of the literature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Abir Salwa Ali
  • Malin Grönberg
  • Birgitte Federspiel
  • Jean-Yves Scoazec
  • Geir Olav Hjortland
  • Henning Grønbæk
  • Morten Ladekarl
  • Seppo W Langer
  • Staffan Welin
  • Lene Weber Vestermark
  • Johanna Arola
  • Pia Österlund
  • Ulrich Knigge
  • Halfdan Sorbye
  • Lars Grimelius
  • Eva Tiensuu Janson
Vis graf over relationer

BACKGROUND: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC.

MATERIALS AND METHODS: Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS).

RESULTS: All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses.

CONCLUSION: In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients.

OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind12
Udgave nummer11
Sider (fra-til)e0187667
ISSN1932-6203
DOI
StatusUdgivet - 2017

ID: 52033212